The Three-Layer Architecture of Epigenetic Drug Targets
Epigenetic drug targeting operates across three mechanistic layers that define how chemical marks are written, erased, and read on chromatin — and each layer has become a distinct pharmaceutical battleground. Writers deposit chemical modifications on DNA or histones: this group includes DNA methyltransferases DNMT1 and DNMT3A, histone methyltransferases EZH2, DOT1L, G9a/GLP (EHMT2/EHMT1), PRMT1 and PRMT5, and the acetyltransferases CBP and EP300. Erasers remove those marks: the histone deacetylase (HDAC) family, the demethylase LSD1/KDM1A, and the KDM5 family of histone demethylases all belong here. Readers — particularly BET bromodomains BRD2, BRD3, BRD4, and BRDT, as well as the SWI/SNF chromatin remodeling complex subunits SMARCA2 and SMARCA4 — translate marks into downstream transcriptional outputs.
A fourth emerging modality sits outside this classical framework: targeted protein degradation. Rather than occupying a catalytic pocket and blocking enzymatic activity, bifunctional PROTAC molecules recruit E3 ubiquitin ligases to tag the target protein for proteasomal destruction. This distinction matters clinically — degradation removes the entire protein, including scaffolding functions that are independent of catalysis and that traditional inhibitors cannot address.
A PROTAC (proteolysis-targeting chimera) is a bifunctional molecule that simultaneously binds a target protein and an E3 ubiquitin ligase, directing the cell’s own protein-degradation machinery to eliminate the target. In the epigenetic context, PROTACs and molecular glues have been developed to degrade EZH2, BRD4, DNMT1, and KDM5B, offering enhanced selectivity and efficacy compared to traditional catalytic inhibitors, according to filings from Arvinas and Dana-Farber Cancer Institute.
Understanding which layer a given target occupies — and whether inhibition or degradation is the more appropriate strategy — is the central analytical question for R&D teams navigating this space. According to WIPO, epigenetic therapies represent one of the fastest-growing patent categories in the pharmaceutical sciences, reflecting the breadth of disease biology that chromatin regulation touches.
Patent Signals: Where Innovation Is Concentrated
Across the 28 patent records retrieved from 2022 to 2025, the most densely patented target classes are BET bromodomains (BRD2/BRD3/BRD4/BRDT), EZH2 and the PRC2 complex, HDAC family members, LSD1, and the SWI/SNF chromatin remodeling complex — each supported by multiple independent assignees filing in parallel. A secondary tier includes DNMT3A, PRMT1, PRMT5, DOT1L, SETD2, G9a/GLP, CBP/EP300, the Menin-MLL interaction, and the KDM5 family.
The assignee landscape is notably heterogeneous. Constellation Pharmaceuticals appears most frequently — across BET bromodomain inhibitors (BRD2/3/4/BRDT), multiple EZH2 inhibitor filings, and G9a/GLP inhibitors. Foghorn Therapeutics has staked a concentrated position in SWI/SNF chromatin remodeling, with filings covering SMARCA2 inhibitors and degraders, SMARCA4 modulators, ARID1A subunit inhibitors, and CBP/EP300 inhibitors. Syndax Pharmaceuticals covers DNMT3A inhibitors for haematological malignancies, Menin-MLL interaction inhibitors for leukemia, and epigenetic combination immunotherapy. Major pharmaceutical companies — including AstraZeneca (EP300/CBP), AbbVie (BET bromodomains for inflammatory disease), and Bristol Myers Squibb (PRMT5 combinations) — are also active, signalling that large-cap pharma has moved beyond watching the space from the sidelines.
In the 2022–2025 epigenetic drug target patent dataset, Constellation Pharmaceuticals is the most frequently appearing assignee, with filings spanning BET bromodomain inhibitors targeting BRD2, BRD3, BRD4, and BRDT; multiple EZH2 inhibitor series; and G9a/GLP histone H3K9 methyltransferase inhibitors.
Academic and non-profit institutions are also prominent contributors. Dana-Farber Cancer Institute filed PROTAC degraders of EZH2, BRD4, and HDAC in early 2025. The Broad Institute filed compositions for treating neurological disorders including Alzheimer’s and Parkinson’s disease using epigenetic modifiers. St. Jude Children’s Research Hospital filed chromatin remodeling inhibitors for paediatric brain tumours including diffuse intrinsic pontine glioma (DIPG). University Health Network filed DOT1L degrader compounds. These academic filings signal that foundational mechanistic research is translating into protectable innovations at a meaningful pace, consistent with trends tracked by NIH-funded epigenomics programmes.
Map the full epigenetic patent landscape across assignees, target classes, and jurisdictions in real time.
Explore Patent Data in PatSnap Eureka →Beyond Inhibition: PROTAC Degraders Redefine Selectivity in Epigenetic Targeting
PROTAC-based degradation of epigenetic regulators represents the most structurally novel development in this patent cohort, with multiple independent filings from 2023 to 2025 targeting the same proteins from different degrader architectures. The core rationale is that epigenetic proteins often exert oncogenic functions through protein-protein interactions and scaffolding roles that are independent of their catalytic domains — functions that catalytic inhibitors, by definition, cannot block.
“Bifunctional molecules — PROTACs and molecular glues — that direct E3 ubiquitin ligases to degrade epigenetic writers, readers, and erasers provide enhanced selectivity and efficacy compared to traditional inhibitors.”
The targets being pursued via degradation in this dataset include EZH2 (Dana-Farber Cancer Institute, 2025; Arvinas, 2024), BRD4 (Dana-Farber Cancer Institute, 2025; Arvinas, 2024), HDAC family members (Dana-Farber Cancer Institute, 2025; Kymera Therapeutics, 2023), DNMT1 (Arvinas, 2024), KDM5B (Arvinas, 2024), DOT1L (University Health Network, 2024), and SMARCA2 (Foghorn Therapeutics, 2023). The breadth of this list — spanning writers, erasers, and readers — confirms that targeted degradation is not a niche strategy confined to one target class but is being applied systematically across the epigenetic target space.
PROTAC bifunctional molecules targeting epigenetic regulators EZH2, BRD4, DNMT1, and KDM5B direct E3 ubiquitin ligases to degrade these proteins entirely, providing enhanced selectivity and efficacy compared to traditional catalytic inhibitors, according to patent filings from Arvinas (WO2024077088A1) and Dana-Farber Cancer Institute (WO2025042789A1).
The parallel pursuit of the same target via both inhibition and degradation creates a distinctive IP dynamic: companies with first-mover inhibitor positions (such as Constellation Pharmaceuticals in EZH2) face the prospect of degrader-based competitors circumventing their composition-of-matter claims. R&D teams should monitor both tracks simultaneously when conducting freedom-to-operate or competitive intelligence analyses, a task well-suited to AI-powered patent platforms such as PatSnap Eureka.
Combination Strategies and Immune Modulation: The New Frontier
Combination approaches — pairing epigenetic agents with each other or with immune checkpoint inhibitors — represent the fastest-growing strategic direction in the retrieved patent dataset, reflecting a recognition that single-agent epigenetic therapies often produce incomplete or transient responses in solid tumours. Three distinct combination logics are visible in the data.
Epigenetic agents combined with immune checkpoint inhibitors
The most clinically significant combination strategy pairs HDAC inhibitors or DNMT inhibitors with PD-1/PD-L1 immune checkpoint inhibitors to enhance anti-tumour immune responses in solid tumours. Syndax Pharmaceuticals (WO2023183855A1) has filed specifically on this approach, arguing that epigenetic reprogramming of the tumour microenvironment sensitises tumours to checkpoint blockade. Epigenomics AG has filed methods of treating cancers with DNMT inhibitors in combination with immune checkpoint inhibitors and other agents.
Intra-epigenetic combinations exploiting synthetic lethality
Oryzon Genomics has filed on combinations of LSD1 inhibitors and BET inhibitors for cancer treatment (US20240165096A1), exploiting the mechanistic interdependence between histone demethylation and bromodomain-mediated transcriptional activation. The Menin-MLL interaction inhibitor filings from Syndax Pharmaceuticals (US20230399314A1) represent a related logic — disrupting a protein-protein interaction within a histone methyltransferase complex, rather than inhibiting a single enzyme, to achieve more complete transcriptional suppression in leukemia.
EZH2 inhibitor combinations for haematological malignancies
Epizyme (WO2024073620A1) has filed methods for treating haematological malignancies — including diffuse large B-cell lymphoma and follicular lymphoma — using tazemetostat or a salt or hydrate thereof in combination with other chemotherapy agents. Constellation Pharmaceuticals (WO2024216323A1) has separately filed on EZH2 inhibitor combinations with at least one additional therapeutic agent for cancer and related conditions.
Combination strategies in the epigenetic drug patent landscape are converging on three logics: (1) pairing HDAC or DNMT inhibitors with PD-1/PD-L1 checkpoint inhibitors to sensitise tumours immunologically; (2) exploiting synthetic lethality between LSD1 and BET pathway inhibition; and (3) combining EZH2 inhibitors such as tazemetostat with chemotherapy for B-cell lymphomas and follicular lymphoma.
The H. Lee Moffitt Cancer Center has filed a broader framework patent on combinatorial epigenetic treatment of cancer (US20230338376A1), covering systems and methods for treating cancer patients with combinations of at least two agents that modify the epigenome — a composition that may have relevance to multiple downstream combination programmes. These combination filings collectively indicate that the field is moving toward personalised, multi-mechanism epigenetic regimens rather than single-agent approaches, a direction consistent with treatment paradigm shifts documented by Nature in oncology research.
Identify combination therapy white space and track competitor filings across epigenetic target classes with PatSnap Eureka.
Analyse Combination Patent Strategies →From Oncology to Neurology: Expanding Disease Applications of Epigenetic Drugs
Cancer dominates the epigenetic drug target patent landscape — but the disease application map is expanding into neurological disorders, inflammatory conditions, and viral infections in ways that were less visible in earlier patent cohorts. This expansion reflects growing mechanistic understanding of how dysregulated chromatin states contribute to pathology beyond tumour biology.
The Broad Institute has filed patent compositions (WO2024050346A1) for treating neurological disorders including Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions using epigenetic modifiers that target DNA methylation and histone modification pathways.
Within oncology, the haematological malignancy indications — diffuse large B-cell lymphoma, follicular lymphoma, and acute myeloid leukemia — remain the most mature application areas, reflecting the approved status of tazemetostat (EZH2 inhibitor) in follicular lymphoma and the clinical validation of the EZH2 target in B-cell lymphomas. Paediatric oncology is a notable emerging sub-segment: St. Jude Children’s Research Hospital has filed chromatin remodeling inhibitors specifically for glioblastoma and paediatric diffuse intrinsic pontine glioma (DIPG), a tumour type with very limited treatment options.
Beyond oncology, BET bromodomain inhibitors are being developed for inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus, as reflected in AbbVie’s filing (US20240131017A1). The DNMT3A inhibitor filings from Syndax Pharmaceuticals are targeted at haematologic malignancies driven by DNMT3A mutations — a mechanistically rational approach given that DNMT3A is among the most frequently mutated genes in acute myeloid leukemia. G9a/GLP histone H3K9 methyltransferase inhibitors from Constellation Pharmaceuticals are described as useful for both cancers and neurological disorders. PRMT5 inhibitors from Bristol Myers Squibb and Prelude Therapeutics cover cancer and viral infections in addition to oncology.
The epigenetic biomarker space is also generating patent activity adjacent to the therapeutic landscape: the US Navy has filed a method for diagnosing concussion by detecting LINE1 methylation site patterns in biological samples (US11965186B1), illustrating how epigenetic marks are being translated into diagnostic applications in non-oncology contexts. The intersection of epigenetic diagnostics and therapeutics is an area that the EPO has identified as a rapidly growing filing category in life sciences patent applications.
AbbVie has filed patent applications (US20240131017A1) covering BET bromodomain inhibitors for treating inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus, extending the BET inhibitor target class beyond its established oncology applications.
For R&D strategists, the disease expansion trend has two practical implications. First, freedom-to-operate analyses for epigenetic compounds must now span oncology, neurology, and immunology patent families simultaneously — the same compound class may be claimed in multiple disease contexts by different assignees. Second, indication-selection decisions for clinical development should be informed by the competitive density of the patent landscape in each disease area, which varies considerably: haematological malignancies are crowded; paediatric brain tumours and neurodegenerative diseases are comparatively open. PatSnap’s platform, covering life sciences innovation intelligence across more than 2 billion data points, enables this kind of multi-indication competitive mapping at scale.